Paragraph IV certification under the Hatch-Waxman Act lets generic drugmakers challenge brand patents to speed up affordable drug entry. Learn how it works, why it succeeds, and how it saves patients billions.
9 December 2025 by Tristan McCarthy
1
10 December 2025
1 December 2025
8 December 2025
6 December 2025
9 December 2025
4 March 2025
30 October 2025
2 December 2025
12 August 2025
1 October 2025